Milestone Pharmaceuticals Inc

NASDAQ:MIST   1:31:06 PM EDT
4.06
-0.32 (-7.31%)
Earnings Announcements

Milestone Pharmaceuticals Reports Third Quarter Financial Results

Published: 11/10/2022 13:11 GMT
Milestone Pharmaceuticals Inc (MIST) - Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update.company Plans to Submit NDA for Etripamil in Psvt to U.S. FDA in Mid-2023 Pending Agency Feedback.
Phase 3 Rapid Trial of Etripamil in Patients With Psvt Achieved Primary Efficacy Endpoint.
Expect Current Cash, Cash Equivalents, and Short-term Investments to Fund Operations Through 2023.
As of September 30, 2022, Milestone Had Cash, Cash Equivalents, and Short-term Investments of $77.2 Million.
Qtrly Loss per Share $0.34.
Q3 Earnings per Share View $-0.41 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $1.17 Million
Adjusted EPS is expected to be -$0.34

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.37

More details on our Analysts Page.